Muscle volume loss after the induction of first-line chemotherapy as a novel prognostic factor in metastatic colorectal cancer patients

被引：0

作者：

Yoshikawa, Yusuke ^{[1
]}

Okabayashi, Koji ^{[1
]}

Hasegawa, Hirotoshi ^{[1
]}

Tsuruta, Masashi ^{[1
]}

Seishima, Ryo ^{[1
]}

Takahashi, Hidena ^{[1
]}

Yamada, Toru ^{[1
]}

Matsui, Shimpei ^{[1
]}

Kondo, Takayuki ^{[1
]}

Shimada, Takehiro ^{[1
]}

Matsuda, Mutsuhito ^{[1
]}

Yahagi, Masashi ^{[1
]}

Asada, Yusuke ^{[1
]}

Sugiura, Kiyoaki ^{[1
]}

Suzuki, Yoshiyuki ^{[1
]}

Tajima, Yuki ^{[1
]}

Nakadai, Junpei ^{[1
]}

Kitagawa, Yuko ^{[1
]}

机构：

[1] Keio Univ, Sch Med, Dept Surg, Tokyo 160, Japan

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 03期

关键词：

D O I：

10.1200/jco.2015.33.3_suppl.558

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

558

引用

页数：1

共 50 条

[31] Bevacizumab in combination with first-line chemotherapy in patients with metastatic colorectal cancer: a meta-analysis
Hu, W.
Xu, W. -S.
Liao, X. -F.
He, H. -J.
MINERVA CHIRURGICA, 2015, 70 (06) : 451 - 458
[32] Oxaliplatin,Fluorouracil and Leucovorin (FOLFOX) as First-line Chemotherapy for Metastatic or Recurrent Colorectal Cancer Patients
Bing Han Ruihua Xu Yanxia Shi Huiyan Luo Xiaojuan Xiang Yuhong Li Li Zhang Tongyu Lin Youjian HeDepartment of Medical Oncology
Chinese Journal of Clinical Oncology, 2007, (06) : 397 - 400
[33] Hope, optimism, and survival in a randomized trial of first-line chemotherapy for patients with metastatic colorectal cancer
Schofield, P.
Stockler, M.
Zannino, D.
Wong, N.
Ransom, D.
Moylan, E.
Simes, R. J.
Price, T. J.
Tebbutt, N. C.
Jefford, M.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[34] Prognostic Factors in First-Line Chemotherapy Treated Metastatic Gastric Cancer Patients: A Retrospective Study
Inal, Ali
Kaplan, M. Ali
Kucukoner, Mehmet
Urakci, Zuhat
Guven, Mehmet
Nas, Necip
Yunce, Muharrem
Isikdogan, Abdurrahman
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2012, 13 (08) : 3869 - 3872
[35] Handy prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer
Chibaudel, B.
Tournigand, C.
Bonnetain, F.
Andre, T.
Lledo, G.
Maindrault-Goebel, F.
Larsen, A. K.
Louvet, C.
de Gramont, A.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[36] Chemotherapy plus bevacizumab versus chemotherapy plus cetuximab as first-line treatment for patients with metastatic colorectal cancer
Bai, Long
Wang, Feng
Li, Zhe-zhen
Ren, Chao
Zhang, Dong-sheng
Zhao, Qi
Lu, Yun-xin
Wang, De-shen
Ju, Huai-qiang
Qiu, Miao-zhen
Wang, Zhi-qiang
Wang, Feng-hua
Xu, Rui-hua
MEDICINE, 2016, 95 (51) : e4531
[37] First-Line Chemotherapy for Metastatic Breast Cancer
Telli, Melinda L.
Carlson, Robert W.
CLINICAL BREAST CANCER, 2009, 9 : S66 - S72
[38] Low muscle attenuation is a prognostic factor for survival in metastatic breast cancer patients treated with first line palliative chemotherapy
Rier, Hanah N.
Jager, Agnes
Sleijfer, Stefan
van Rosmalen, Joost
Kock, Marc C. J. M.
Levin, Mark-David
BREAST, 2017, 31 : 9 - 15
[39] Relative dose intensity of first-line triplet chemotherapy in metastatic colorectal cancer
Hoba, Julien
Grancher, Adrien
Hautefeuille, Vincent
Turpin, Anthony
Bouhier-Leporrier, Karine
Galais, Marie-Pierre
Bignon, Anne-Laure
Di Fiore, Aude
Desgrippes, Romain
Miglianico, Laurent
Avisse, Benoit
Baconnier, Mathieu
Lam, You-Heng
Dutherage, Marie
Sefrioui, David
Le Malicot, Karine
Phelip, Jean-Marc
Michel, Pierre
Gillibert, Andre
Di Fiore, Frederic
DIGESTIVE AND LIVER DISEASE, 2025, 57 (01) : 30 - 37
[40] First-line chemotherapy with raltitrexed in metastatic colorectal cancer: An AGEO multicentre study
Gallois, C.
Hafliger, E.
Auclin, E.
Perret, A.
Artru, P.
Coutzac, C.
Turpin, A.
Pellat, A.
Randrian, V.
Basile, D.
Faroux, R.
Locher, C.
Hautefeuille, V.
Dubreuil, O.
Palmieri, L-J.
Dior, M.
Taieb, J.
ANNALS OF ONCOLOGY, 2020, 31 : S430 - S430

← 1 2 3 4 5 →